Compare · NVO vs SAVA
NVO vs SAVA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Cassava Sciences Inc. (SAVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SAVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 115.1x SAVA ($1.59B).
- Over the past year, NVO is down 45.7% and SAVA is up 11.2% - SAVA leads by 56.9 points.
- NVO has hit the wire 8 times in the past 4 weeks while SAVA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 9 for SAVA).
- Company
- Novo Nordisk A/S
- Cassava Sciences Inc.
- Price
- $41.01-4.51%
- $2.38+12.80%
- Market cap
- $183.15B
- $1.59B
- 1M return
- -10.44%
- +16.95%
- 1Y return
- -45.66%
- +11.21%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Cassava Sciences Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SAVA
- SEC Form 10-K filed by Cassava Sciences Inc.
- Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
- Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Cassava Announces Closure of U.S. Department of Justice Investigation
- Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease
- Cassava Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form 8-K/A filed by Cassava Sciences Inc.
- Cassava Sciences Inc. filed SEC Form 8-K: Other Events